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Abstract. We have transfected recombinant plasmids carrying 
5 ' c-myc sequences linked to the reporter gene chlorampheni­
col acetyl-transferase (cat) and to the selectable marker ami­
noglycoside phosphotransfarase (aph) into rat fibroblasts and 
obtained stable transfectants. The response to cis-platin of 
these cell lines was studied. At 5 X 10sM concentration 
cis-platin stimulates cat gene expression 9 and 11 fold respec­
tively in cell lines containing constructs with c-myc promoter 
sequences truncated at -2319 and -350 relative to c-myc RNA 
start site PI. A third cell line expressing a myc/cat recombinant 
truncated at -290 shows no response to cis-platin, thus 
defining a cis-platin responsive element between coordinates 
-290 and -350 on the myc promoter region. 
The product of the c-myc proto-oncogene is a nuclear protein 
involved in the control of cellular proliferation and dif­
ferentiation. Perturbation of c-myc gene expression can be 
observed in both experimentally induced and naturally occur­
ring tumors in chickens, rodents, rats and humans (1-5). With 
few exceptions it is deregulation of gene expression rather 
than mutational alteration to the myc protein that is responsi­
ble for activation of the oncogenic potential of c-myc. 
The regulation of c-myc gene expression is complex and is 
controlled not only at the level of transcription initiation but 
also through a block to transcript elongation (6), stabiliza­
tion of c-myc RNA (7,8) and translation of c-myc transcripts 
(9). It is clear that transcriptional regulation of c-myc is 
complex and that gene expression is controlled by both 
positive and negative cis-acting regulatory domains (10-14). 
Cis-platin has been extensively used as an anti-cancer drug 
in a variety of human tumors (for a review see ref. 15). 
Although its specific site of action is not certain, interaction 
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with DNA has been suggested as the critical target (16). 
Recently we have shown that cis-platin stimulates expression 
from the human immunodeficiency virus long terminal repeat 
in both rat (17) and human (18) cells. 
In the present study we have shown a stimulatory effect of 
cis-platin on the 5' flanking sequences of human c-myc and 
we have located sequences between coordinates -290 and -350 
from the first major (P,) cap site. 
Materials and Methods 
Recombinant plasmids and cell lines. Plasmids p324, p330 and p323 
carrying 5' c-myc flanking sequences linked to the reporter cat gene are 
depicted in Figure 1. The rat 208F cells and their transfection with 
recombinant plasmids have been described previously (19). 
CA Τ assays. Cells were grown exponentially in Ham's medium containing 
10% fetal calf scrum and assayed for CAT activity as previously described 
(20). 
Results 
Cis-platin regulates expression from the c-myc promoter. 
RF324A cells harbor a recombinant plasmid containing 2319 
bp of 5' flanking c-myc DNA and 511 bp from the first exon 
El of the c-myc gene linked to the bacterial chloramphenicol 
acetyltransferase (cat) gene, as shown in Figure 1. The effect 
of cis-platin on the RF324A cells was examined. As shown in 
the autoradiograph of Figure 2a and the histogram of Figure 
2b, the amount of CAT produced in cell line RF324A varies 
with the amount of cis-platin administered to the cells. 
Cis-platin at a concentration of 1 X10'6M (lane 3) has little 
effect on the amount of CAT activity produced by cell line 
RF324A. Increasing the concentration of cis-platin to an 
optimum of 5 x 10"5M results in a corresponding increase in 
CAT activity by 5-fold (lanes 4 and 5). At a higher concentra­
tion (1 x 10"4M) CAT activity is shown to decrease (lane 6), 
perhaps due to the cytotoxic effects of the drug. 
As shown in the autoradiograph of Figure 3a and the 
histogram of Figure 3b, the optimal time period of exposure 
to cis-platin is 24h. Longer exposure results in cell death due 
to cytoxicity (data not shown). 
0250-7005/91 $2.00+.40 1339 
ANTICANCER RESEARCH /;.• 1339-1342 (1991) 
ρ 3 2 4 
Hindu 
-2319 9 El Β C A T 
_ 3 A c C m 
P 3 3 0 
HtndflKPvuQ) 
- 3 5 0 0 fjß -1 Ac C m 




Ε' Β f u i 
Figure 1. A 2830 bp Hindllll BamHI fragment from human c-myc containing 
Sllbp of 5 'flanking sequence was linked to the coding sequences of the cat gene. 
5 ' terminal deletions of the myc promoter were constructed by Pvull or Rsal 
cleavage followed by Hindlll linker addition and similarly linked to the cat gene. 
The hybrid myc/cat constructs were then cloned into the multi-cloning site of 
vector p304 (21) containing the aph gene. 
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Localization of cis-platin responsive sequences in the c-myc 
promoter. Two other cell lines RF330A and RF323A harbor­
ing the plasmids p330 and p323 (Figure 1) respectively were 
tested for their response to c«-platin. As shown in the 
autoradiograph of Figure 4a and the histogram of Figure 4b, 
cell lines RF324A and RF330A respond to ris-platin induc­
tion measured by 9 and 11 fold increase in cat gene expression 
respectively; however, cell line RF323A failed to respond. 
These results define a m-platin responsive region between 
-290 and -350 bp upstream of the c-myc P, cap site. 
Discussion 
Cw-platin has been used extensively as an anti-cancer drug in 
a variety of human tumors, including head and neck (15). 
While the mechanism of action of ds-platin is uncertain, it 
may exert its cytotoxic effect by binding directly with DNA. 
The c-myc oncogene is implicated in the genesis of a number 
of human neoplasia also including head and neck (for a 
review see ref. 22). We have therefore initiated a study 
designed to discover whether c-myc gene expression may be 
altered by cw-platin. 
We have defined a region within the 5' flanking sequence 
of human c-myc delimited by coordinates -290 to -350 which 
responds positively to cw-platin by increasing the level of 
gene expression initiated from the c-myc promoter. A regula­
tory element within this region has previously been identi­
fied. This element is, in contrast, responsible for down-
regulation of c-myc expression (11) and has been shown to 
bind the oncogene fos or an antigenically related protein (23). 
Whether the same element is capable of responding to 
cw-platin and is therefore resonsible for the observed positive 
regulatory response we have described is unknown. In this 
context, a composite glucocorticoid response element 
usptream of the mouse proliferin gene has been identified 
which binds transcription factor AP-1, one component of 
which is the fos oncogene, and which confers on linked 
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Figure 2. Induction of CAT activity by cis-platin. 
a. Chromatogram of representative CAT assay with extracts from recipient 208F 
and transfectant RF324A cells with and without treatmentl with cis-platin. 
b. Histogram of recorded CA Τ activities. 208F and RF324A cells were plated at 
1.5x10* ceUsmcm2 flask in Ham's SF12 medium containing 10% FCSat3TC. 
24 hours later the medium was replaced with Ham's SF 12 containing 0.5% FCS 
and left for another 24 hours at3TC. The medium was then replaced with Ham's 
SF 12 containing 5% FCS and varying concentrations of cis-platin. Cells were 
harvested 24 hours later and tested for CA Τ activity as described in Materials and 
Methods. Relative values of CAT activity in 208F and RF324A cells were 2.2 
pmole acetylated chloramphenicol!mg protein per hour incubation respectively. 
The average from three experiments is given. Standard deviation was less than 
5% of the average values. 
promoters either positive or negative glucocorticoid regula­
tion, depending on physiological conditions (24). 
In many tumor systems involving the c-myc oncogene, 
elevated expression of c-myc has been demonstrated. In this 
report, too, the effect of ds-platin is to elevate myc express­
ion. Whether the in vivo anti-tumor action of or-platin 
directly involves interaction with the c-myc oncogene is 
therefore not clear, since a decrease rather than increase in 
myc expression might be expected. Further understanding of 
this phenomenon awaits analysis of c-myc gene expression in 
tumor material isolated from individuals after oy-platin treat­
ment. 
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Figure 3. u.Induction of CAT activity in RF324A cells by cis-platin at various 
times post-treatment. 
b. CA Τ values were computed and are presented in histogram form as described 
in Figure 2. 
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Figure 4. Induction of CAT activity by cis-platin in rat cells carrying deletions of 
the c-myc promoter region. 
a. Chromatograms for representative CA Τ assays with extracts from RF324A, 
RF330A and RF323A cells treated with 5x10 M cis-paltin. 
b. CA Τ values were computed and are presented in histogram form as described 
in Figure 2. 
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